Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
ACS Pharmacology & Translational Science|August 15, 2024
Effect of Linker Entities on Pharmacokinetics of 111In-Labeled Prostate-Specific Membrane Antigen-Targeting Ligands with an Albumin BinderNobuki Kazuta, Kazuma Nakashima, Hiroyuki Watanabe, et al.
Nuclear Medicine and Biology|April 13, 2024
Synthesis and evaluation of novel trifunctional chelating agents for pretargeting approach using albumin binder to improve tumor accumulationShohei Tsuchihashi, Kazuma Nakashima, Hiroyuki Watanabe, et al.
ACS Medicinal Chemistry Letters|October 20, 2022
Application of the Chelator-Based Clickable Radiotheranostic Platform to Moderate-Molecular-Weight LigandsKazuma Nakashima, Shimpei Iikuni, Hiroyuki Watanabe, et al.
Annals of Nuclear Medicine|November 25, 2024
Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agentKazuma Nakashima, Hiroki Shimohara, Hiroyuki Watanabe, et al.
Journal of Labelled Compounds & Radiopharmaceuticals|June 5, 2024
Synthesis and Evaluation of a Cathepsin B-Recognizing Trifunctional Chelating Agent to Improve Tumor Retention of RadioimmunoconjugatesHiroki Jinda, Kazuma Nakashima, Hiroyuki Watanabe, et al.
Molecular Pharmaceutics|July 14, 2026
Improving Pharmacokinetics of PSMA/GRPR-Targeting Radiolabeled Heterodimer through Enhanced Albumin BindingShohei Tsuchihashi, Kazuma Nakashima, Hiroyuki Watanabe, et al.
Chemical Communications (Cambridge, England)|November 7, 2025
A novel bivalent albumin binder for enhanced tumor retention of a fibroblast activation protein-targeted radioligandKazuma Nakashima, Keisei Yamaguchi, Kosuke Saito, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|October 7, 2025
Control of pharmacokinetics of radioimmunoconjugates using chelating agents containing poly(ethylene glycol)Kazuma Nakashima, Hiroki Jinda, Hiroki Shimohara, et al.
Bioconjugate Chemistry|June 12, 2026
Development of Novel Cholecystokinin 2 Receptor-Targeted Radioligand Containing Albumin Binder for Efficient 111In/177Lu TheranosticsTakahiro Yamamoto, Kazuma Nakashima, Nobuki Kazuta, et al.
Molecular Pharmaceutics|March 24, 2026
Influence of the Binding Valency of Anti-HER2 Biparatopic Antibodies on Biodistribution in an SK-OV-3 Tumor Xenograft ModelHiroki Akiba, Kazuma Nakashima, Takayoshi Ichinose, et al.
Pageof 3